Dasatinib , ≥99% , 302962-49-8

Synonym(s):
BMS 354825;BMS354825;BMS-354825;N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide

CAS NO.：302962-49-8

Empirical Formula: C22H26ClN7O2S

Molecular Weight: 488.01

MDL number: MFCD11046566

EINECS: 801-607-0

PRODUCT Properties

• Melting point: 275-286°C
• Density: 1.408±0.06 g/cm3(Predicted)
• storage temp.: Sealed in dry,Store in freezer, under -20°C
• solubility: Soluble in DMSO (up to 200 mg/ml).
• pka: 10.94±0.70(Predicted)
• form: White powder.
• color: White or off-white
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 2 months.
• InChIKey: ZBNZXTGUTAYRHI-UHFFFAOYSA-N
• SMILES: S1C(C(NC2=C(C)C=CC=C2Cl)=O)=CN=C1NC1C=C(N2CCN(CCO)CC2)N=C(C)N=1
• CAS DataBase Reference: 302962-49-8(CAS DataBase Reference)

Description and Uses

Dasatinib, developed and marketed by Bristol Myers, is the first approved oral tyrosine kinase inhibitor which binds to multiple conformations of ABL kinase for the treatment of two leukemia indications: chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Dasatinib is a highly potent, ATPcompetitive ATPcompetitive kinase inhibitor which, at nanomolar concentrations, inhibits BCR-ABL, SRC family, c-KIT, EPHA2 and PDGFR-B.

Safety

• Symbol(GHS): GHS05,GHS08,GHS09
• Signal word: Danger
• Hazard statements: H315-H318-H351-H361fd-H372-H410
• Precautionary statements: P202-P273-P280-P302+P352-P305+P351+P338-P308+P313
• HS Code: 29341000
• Excepted Quantities: Max Inner Pack (30g or 30ml) and Max Outer Pack (1Kg or 1L)